Palatin Technologies (PTN)
(Delayed Data from AMEX)
$1.58 USD
-0.11 (-6.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.57 -0.01 (-0.63%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth F Momentum D VGM
Brokerage Reports
0 items in cart
Palatin Technologies, Inc. [PTN]
Reports for Purchase
Showing records 181 - 200 ( 201 total )
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hopefully a "Satisfying Event" To Come; FSD Phase IIb Data Soon
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Top-line Results of Phase IIb FSD Study of BMT Expected in 4Q12
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
AZD2820 Discontinued; No Surprises; Focus Remains on FSD
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Hiccup, Likely Temporary, for AZD2820 Study; Target to $4.75
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F3Q12 Results; Expect Results from 2 Studies by Year End
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Positive FDA AdCom Vote for Lorcaserin; We See Positive Impact for Palatin
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage; Rating, PT and Estimates Under Review
Provider: Roth Capital Partners, Inc.
Analyst: MARTIN J
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Palatin Technologies, Inc.
Industry: Medical - Biomedical and Genetics
F2Q Results, Completing Phase IIb Enrollment, Obesity Program Advancing
Provider: Roth Capital Partners, Inc.
Analyst: MOSKOWITZ D